XORTX Pharma Corp. – a company focused on the development of drugs to treat orphan and non-orphan kidney diseases – is pleased to announce the Issuance of a U.S. Patent No. 9,155,740, entitled “COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA RELATED HEALTH CONSEQUENCES”. A patent with claims to the use of all uric acid lowering agents to treat diabetic nephropathy, for example, drugs to limit production of uric acid – allopurinol and febuxostat; uricosuric drugs that increase excretion such as – probenecid and benzbromarone; or uricase drugs that breakdown uric acid in the circulatory system would fall within the claims.
About Diabetic Nephropathy: Diabetic nephropathy is a common complication of diabetes and the leading cause of chronic kidney disease in the developed world. Approximately 30% of persons with diabetes develop diabetic nephropathy, manifested as protein in urine (albuminuria) and/or decreased filtration ability by kidneys (glomerular filtration rate (GFR)). Even mild degrees of albuminuria and decrease in glomerular filtration rate are associated with significantly increased risks of cardiovascular disease, end-stage renal disease, and premature deaths. Despite some benefit from blood pressure control and glucose control, patient’s declining kidney function remains inadequately treated. Recent studies suggest a new mechanism of disease action may be causing endothelial function and accelerating decline of kidney function in these patients – dysfunctional uric acid metabolism. Clinical pilot studies suggest that managing purine and uric acid metabolism in diabetic nephropathy may offer a new means of attenuating decline of glomerular filtration rate.
Dr. Allen Davidoff commented, “This newly granted patent represents an important key element of the XORTX Pharma Corp patent portfolio and covers claims for the treatment of diabetic nephropathy in the United States.” and stated further “Recent pilot clinical studies have shown that aberrant uric acid metabolism may play a role in accelerating kidney dysfunction and decline in several diseases.  These positive results strongly suggest that managing uric acid metabolism has the potential to help diabetic nephropathy patients with declining kidney function.”
About Diabetes: There are three main types of diabetes: Type 1, Type 2 and Gestational Diabetes.  Type 1 diabetes is primarily a pediatric disease with diagnosis usually occurring at an age less than 20yrs.  Type 1 diabetes is considered to be an auto-immune disease where the pancreas produces very little insulin or no insulin at all. Individuals diagnosed with type 1 diabetes have the disease for life and are dependent on insulin shots or pump. Type 2 diabetes as well as a stage before diabetes called pre-diabetes is usually found in people who are overweight. Type 2 diabetes is considered a lifestyle disease because it is normally triggered by living a fairly sedentary life, but incidence also increases with age.  Over the past three decades, the number of people with diabetes mellitus has more than doubled globally, making it one of the most important public health challenges to all nations. Type 2 diabetes mellitus (T2DM) and prediabetes are increasingly observed among children, adolescents and younger adults. Gestational diabetes occurs in about 4% of pregnancies and is a condition usually seen in the second trimester. The condition usually disappears after the baby is born, and often re-occurs with subsequent pregnancies.
Pre-diabetes and diabetes represent a growing epidemic worldwide including North America.  In the US it has been estimated that approximately 86 million individuals have prediabetes and approximately 29 million have diabetes. Worldwide, it is estimated that 360 million people have diabetes and that number is projected to increase to 552 million by 2030.  Progression of untreated diabetes can damage organs including tissue of kidneys, eyes, peripheral nerves, vascular tree, skin and loss of limbs in the lower extremities due to poor or deteriorating circulation.
Pre-diabetes and diabetes are associated with symptoms that include high blood pressure, central obesity, high serum lipids, cholesterol and poor glucose control.  Importantly, clinical studies have shown that patients can benefit from blood pressure and glucose control.
About XORTX Pharma Corp. is a pharmaceutical company dedicated to the discovery, development and commercialization of therapies for rare diseases –orphan indications – and diseases caused by disrupted uric acid metabolism that will improve patient health throughout the world. The primary focus of XORTX Pharma Corp. is based on developing treatments to better manage uric acid metabolism for treatment of autosomal dominant polycystic kidney disease when accompanied by hyperuricemia.  Secondary programs include the development of uric acid lowering agents to treat diabetes, and treat diabetic nephropathy. XORTX Pharma Corp. is a privately held company. For more information, please visit our web site at www.xortx.com.
Forward-Looking Statement Disclaimer
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Risks, uncertainties and factors that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks, uncertainties and factors related to the fact that: we, together with our collaborative partners, may not be able to successfully develop all or any of our current or future products and may not be able to obtain regulatory approval in targeted indications for our current or future products in all markets; we may not achieve or maintain profitability; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital as and when required; we depend on our collaborative partners to perform their obligations under licensing or other collaborative agreements; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; any of our products that obtain regulatory approval will be subject to extensive post-market regulation that may affect sales, marketing and profitability; any of our products that are successfully developed may not achieve market acceptance; we rely on third parties for the continued supply and manufacture of our products and have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters, including with respect to our ability to protect our intellectual property; we face increased competition from pharmaceutical and biotechnology companies; and other. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.